

## Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision<sup>i</sup>

Actives substances(s): Danuglipron

Latest Decision number(s): 1) P/0085/2023

Corresponding PIP number(s): 1) EMEA-002944-PIP02-22

If the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Condition: Treatment of Obesity

Indication: Adjuvant therapy in children and adolescents from 6 years to less than 18 years of age with obesity or overweight with at least one weight-related comorbidity.

☒ has been discontinued

for the following reason(s): (tick all that apply)

- ☐ (possible) lack of efficacy in adults
- ☐ (possible) lack of efficacy in children
- ☐ (possible) unsatisfactory safety profile in adults
- ☐ (possible) unsatisfactory safety profile in children
- ☐ commercial reasons (please specify: )
- ☐ manufacturing / quality problems

☐ other regulatory action (please specify: )

☒ other reason (please specify: After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation:

On 14 April 2025, Pfizer Inc, announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.

Company Press Release: [Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron | Pfizer](#).

Date: 17/04/2025

Contact for inquiries from interested parties: Medical Information

Telephone: +44 (0)1304 616161

Email: [medical.information@pfizer.com](mailto:medical.information@pfizer.com)